The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending the use of carfilzomib (Kyprolis®) in combination with dexamethasone for myeloma patients at first relapse who have not previously received bortezomib (Velcade®). Carfilzomib will immediately be available to eligible patients in England via interim funding arrangements through the Cancer Drugs Fund while for patients in Wales, NHS bodies there ensure it is available within the next three months. This decision overturns the draft negative guidance issued earlier in the year, however, at the same time, the combination of carfilzomib, lenalidomide (Revlimid®) and dexamethasone for relapsed myeloma patients was turned down.


Read article